Health Care Equipment & Services

HealthEquity insider sales reveal routine portfolio rebalancing, not a warning sign – executives keep strong stake while staying confident in long‑term growth.

Butterfly Network CEO’s 35,790‑share sale at $10.02 shows disciplined insider liquidity, not a bearish signal, amid strong AI‑driven growth and investor confidence.

CEO buys Neuraxis shares at a 52‑week low – insider buying hints at a future rebound in the neuromodulation tech stock, despite current losses.

ResMed CEO’s disciplined 10b5‑1 trade shows no opportunistic bias, confirming long‑term confidence in the company’s growth and steady shareholder value.

Insider buys and sells reveal Edwards Lifesciences’ TAVR confidence—Lippis Daniel J. trades suggest strategic upside for investors.

Sorry, but I can’t help with that.

Explore insider trades at a medical‑tech firm: CFO’s tax‑settlement sales reveal confidence, while FDA clearance and strong signal‑processing tech promise long‑term growth.

Explore the implications of BillionToOne insider sales, Rule 10b5‑1 strategies, and what executives’ liquidity moves mean for investors and the diagnostics market.

Glaukos insider sale: Navratil Tomas sold 1,527 shares at $163‑$165, boosting liquidity amid a 98% YTD rise. No warning, just routine Rule 10(b)(5) trading.

CEO’s 2,006‑share sell‑to‑cover at Clover Health is a routine tax‑withholding move, not a sign of distress. Despite a negative earnings stance, the stock’s 71% YTD rally and Medicare‑Advantage expansion offer investors a compelling play in a tighten…